Jnana Therapeutics Closes $50 Million Series B Financing To Advance Lead Pku Program And Small Molecule Pipeline Based On Next Gen Chemoproteomic Platform

Aug 18, 2021•about 4 years ago

Amount Raised

$50 Million

Round Type

series b

BostonTransportationHealth Care

Description

Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, today announced the closing of a $50 million Series B financing. The financing was led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures.

Company Information

Company

Jnana Therapeutics

Location

Boston, Massachusetts, United States

About

Jnana Therapeutics is a biotechnology company utilizing a next generation chemoproteomic platform to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters. Jnana is focused on developing best-in-class therapies to treat a wide range of diseases, including immune-mediated, neurological and metabolite-dependent diseases. Headquartered in Boston, Jnana is founded by world-renowned scientists and backed by leading life science investors. For more information, please visit www.jnanatx.com and follow us on Twitter and on LinkedIn.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Jnana Therapeutics Closes $50 Million Series B Financing To Advance Lead Pku Program And Small Molecule Pipeline Based On Next Gen Chemoproteomic Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information